Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia

  1. Schmid, Christoph ORCID logo
  2. LABOPIN, Myriam ORCID logo
  3. Schaap, Nicolaas
  4. Veelken, Hendrik ORCID logo
  5. Brecht, Arne
  6. Stadler, Michael
  7. Finke, Juergen
  8. Baron, Frederic ORCID logo
  9. Collin, Matthew ORCID logo
  10. Bug, Gesine
  11. Ljungman, Per ORCID logo
  12. Blaise, Didier ORCID logo
  13. Tischer, Johanna
  14. Bloor, Adrian ORCID logo
  15. Kulagin, Alexander ORCID logo
  16. Giebel, Sebastian ORCID logo
  17. Gorin, Norbert-Claude
  18. Esteve Reyner, Jordi ORCID logo
  19. CICERI, Fabio ORCID logo
  20. Savani, Bipin ORCID logo
  21. Nagler, Arnon
  22. Mohty, Mohamad ORCID logo

Download
s41409-021-01515-3.pdf 997,04KB
WeightNameValue
1000 Titel
  • Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
1000 Autor/in
  1. Schmid, Christoph |
  2. LABOPIN, Myriam |
  3. Schaap, Nicolaas |
  4. Veelken, Hendrik |
  5. Brecht, Arne |
  6. Stadler, Michael |
  7. Finke, Juergen |
  8. Baron, Frederic |
  9. Collin, Matthew |
  10. Bug, Gesine |
  11. Ljungman, Per |
  12. Blaise, Didier |
  13. Tischer, Johanna |
  14. Bloor, Adrian |
  15. Kulagin, Alexander |
  16. Giebel, Sebastian |
  17. Gorin, Norbert-Claude |
  18. Esteve Reyner, Jordi |
  19. CICERI, Fabio |
  20. Savani, Bipin |
  21. Nagler, Arnon |
  22. Mohty, Mohamad |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-11-08
1000 Erschienen in
1000 Quellenangabe
  • 57(2):215-223
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41409-021-01515-3 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821014/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • We report on 318 patients with acute leukemia, receiving donor lymphocyte infusion (DLI) in complete hematologic remission (CHR) after allogeneic stem cell transplantation (alloSCT). DLI were applied preemptively (preDLI) for minimal residual disease (MRD, n = 23) or mixed chimerism (MC, n = 169), or as prophylaxis in high-risk patients with complete chimerism and molecular remission (proDLI, n = 126). Median interval from alloSCT to DLI1 was 176 days, median follow-up was 7.0 years. Five-year cumulative relapse incidence (CRI), non-relapse mortality (NRM), leukemia-free and overall survival (LFS/OS) of the entire cohort were 29.1%, 12.7%, 58.2%, and 64.3%. Cumulative incidences of acute graft-versus-host disease (aGvHD) grade II-IV°/chronic GvHD were 11.9%/31%. Nineteen patients (6%) died from DLI-induced GvHD. Age ≥60 years (p = 0.046), advanced stage at transplantation (p = 0.003), shorter interval from transplantation (p = 0.018), and prior aGvHD ≥II° (p = 0.036) were risk factors for DLI-induced GvHD. GvHD did not influence CRI, but was associated with NRM and lower LFS/OS. Efficacy of preDLI was demonstrated by decreasing MRD/increasing blood counts in 71%, and increasing chimerism in 70%. Five-year OS after preDLI for MRD/MC was 51%/68% among responders, and 37% among non-responders. The study describes response and outcome of DLI in CHR and helps to identify candidates without increased risk of severe GvHD.
1000 Sacherschließung
lokal Lymphocyte Transfusion/adverse effects [MeSH]
lokal Cancer
lokal Humans [MeSH]
lokal Lymphocytes [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Leukemia, Myeloid, Acute/complications [MeSH]
lokal Recurrence [MeSH]
lokal Acute Disease [MeSH]
lokal Article
lokal Immunotherapy
lokal Transplantation Conditioning/adverse effects [MeSH]
lokal Graft vs Host Disease/etiology [MeSH]
lokal Cancer immunotherapy
lokal Hematopoietic Stem Cell Transplantation/methods [MeSH]
lokal Neoplasm, Residual [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-7070-487X|https://orcid.org/0000-0003-4514-4748|https://frl.publisso.de/adhoc/uri/U2NoYWFwLCBOaWNvbGFhcw==|https://orcid.org/0000-0002-9108-3125|https://frl.publisso.de/adhoc/uri/QnJlY2h0LCBBcm5l|https://frl.publisso.de/adhoc/uri/U3RhZGxlciwgTWljaGFlbA==|https://frl.publisso.de/adhoc/uri/Rmlua2UsIEp1ZXJnZW4=|https://orcid.org/0000-0002-2944-3812|https://orcid.org/0000-0001-6585-9586|https://frl.publisso.de/adhoc/uri/QnVnLCBHZXNpbmU=|https://orcid.org/0000-0002-8281-3245|https://orcid.org/0000-0002-5684-9447|https://frl.publisso.de/adhoc/uri/VGlzY2hlciwgSm9oYW5uYQ==|https://orcid.org/0000-0003-4550-220X|https://orcid.org/0000-0002-9589-4136|https://orcid.org/0000-0002-4827-4401|https://frl.publisso.de/adhoc/uri/R29yaW4sIE5vcmJlcnQtQ2xhdWRl|https://orcid.org/0000-0002-8056-648X|https://orcid.org/0000-0003-0873-0123|https://orcid.org/0000-0002-3304-9965|https://frl.publisso.de/adhoc/uri/TmFnbGVyLCBBcm5vbg==|https://orcid.org/0000-0002-7264-808X
1000 Hinweis
  • DeepGreen-ID: c3f39dd7abc74318aef5c0f21f55f7bc ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6442888.rdf
1000 Erstellt am 2023-04-26T16:07:50.177+0200
1000 Erstellt von 322
1000 beschreibt frl:6442888
1000 Zuletzt bearbeitet Tue Oct 24 07:49:14 CEST 2023
1000 Objekt bearb. Tue Oct 24 07:49:14 CEST 2023
1000 Vgl. frl:6442888
1000 Oai Id
  1. oai:frl.publisso.de:frl:6442888 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source